Oncosoft (CEO Jin-sung Kim), a specialized company in AI radiotherapy software, announced on the 10th that it was recently selected as the "2025 Best AI Radiotherapy Solution in Asia-Pacific" by 'MedTech Outlook APAC.'
'MedTech Outlook APAC' is a magazine targeting over 100,000 medical professionals in the Asia-Pacific region. After subscriber recommendations and expert reviews, Oncosoft was exclusively selected in this category.
Oncosoft's core products, 'OncoStudio' (automated contouring) and 'OncoFlow' (workflow management), are currently implemented in more than 100 hospitals worldwide, gaining recognition for their technological prowess. In the Asia-Pacific region, the company obtained medical device certification in Japan earlier this year and is currently operating about 40 demo sites, recently recording its first sales. It also achieved sales performance in Singapore, where licensing is expected to be completed within the year, and is proceeding with licensing in Malaysia.
Based on these achievements, the company is accelerating its expansion into global markets such as North America and Europe. In North America, the Mayo Clinic has adopted Oncosoft's AI solutions. In the Middle East, the company is supplying products to the UAE (United Arab Emirates). According to the company, it received numerous demo requests from medical institutions in Europe and South America at the recent ASTRO (American Society for Radiation Oncology) 2025.
Jin-sung Kim, CEO of Oncosoft, stated, "This award is official recognition that our company is a leading firm in the field of AI radiotherapy in the Asia-Pacific region. Based on our Asia-Pacific foundation and global references, we will target the world market and leap forward as a global leader."
Oncosoft plans to strengthen its technical leadership in the global radiotherapy market through AI solutions currently under development, such as 'OncoRPT' (Radiopharmaceutical Therapy) and 'OncoPlan' (Particle Therapy).
